Zymeworks (FRA:ZA8) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ZA8 Zymeworks Inc FRA:ZA8
59 GF Score
Price €19.92
GF Value €21.86
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Zymeworks FFO per Share?

FFO per Share only applies to REITs.

FRA:ZA8
59GF Score
Zymeworks Inc FRA:ZA8
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zymeworks (FRA:ZA8) Overvalued in 2026?

Based on GuruFocus' analysis, Zymeworks stock appears to be undervalued. The current stock price of €19.92 is trading 8.9% below its estimated GF Value™ of €21.86. GuruFocus considers Zymeworks to be Fairly Valued.

Key valuation signals for FRA:ZA8:

  • FFO per Share:
  • GF Value™: €21.86 vs. price of €19.92 (8.9% below fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the FRA:ZA8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zymeworks Business Description

Other Exchanges ZYME:USAZA8:Germany
Address 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
59GF Score

Get the complete analysis for FRA:ZA8

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.92
Price
€21.86
GF Value